 OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2020 GLOBE NEWSWIRE -- Oxford Immunotec Global PLC Nasdaq: OXFD the Company, a global, high-growth diagnostics company, today announced the release of data from a prospective cohort study in keyworkers in the UK a collaboration between the Company and Public Health England PHE. The data demonstrates that SARS-CoV-2 reactive T cells may be sufficient to give protection from COVID-19 and that serology alone may underestimate those at lower risk of clinical SARS-CoV-2 infection. 